Lupin Somerset facility gets EIR from USFDA - Video
|
Overview
Global pharma major, Lupin Limited, today announced that the company has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.
Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action
For more details, check out the full details on the link below:
Lupin Gets USFDA EIR For Somerset Facility
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
